Drug
5ARI + AB
5ARI + AB is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Phase Distribution
No phase data available
Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(3)
Detailed Status
Completed3
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Trials by Status
completed3100%
Recent Activity
0 active trials
Showing 3 of 3
completed
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
NCT01332435
completed
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
NCT01332487
completed
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
NCT01386983
Clinical Trials (3)
Showing 3 of 3 trials
NCT01332435
Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use
NCT01332487
Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia
NCT01386983
Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3